How Much Does Jatenzo Cost in Wyoming in 2026?

Wyoming Retail Pricing for Jatenzo

The average cash-pay price for Jatenzo at Wyoming retail pharmacies sits at roughly $900 per month in 2026. That figure mirrors Tolmar Pharmaceuticals' wholesale acquisition cost and has remained stable since the drug's FDA approval in March 2019 for men with hypogonadism due to certain medical conditions 1.

Wyoming's pharmacy market is small. The state has approximately 130 retail pharmacy locations spread across 23 counties, and pricing variation between outlets is minimal for brand-name specialty drugs. Unlike injectable testosterone cypionate, which can cost as little as $30 to $50 per month in generic form 2, Jatenzo occupies a premium tier because no AB-rated generic oral testosterone undecanoate exists in the United States as of May 2026.

The oral route does offer distinct advantages. Swerdloff et al. demonstrated in a key phase 3 trial (N=166) that oral testosterone undecanoate restored eugonadal testosterone levels (300 to 1,100 ng/dL) in 87% of hypogonadal men at the 237 mg twice-daily dose 3. Patients avoid needles entirely, and the twice-daily dosing with a fat-containing meal supports lymphatic absorption, bypassing first-pass hepatic metabolism 4.

For men in Wyoming who pay cash, the annualized cost of Jatenzo approaches $10,800. That price point makes exploring insurance coverage, manufacturer assistance, and compounded alternatives a practical necessity for most patients.

Insurance Coverage in Wyoming

Commercial insurance coverage for Jatenzo in Wyoming varies by carrier, formulary tier, and prior authorization requirements. Most plans that do cover Jatenzo place it on a specialty or non-preferred brand tier, resulting in copays that can range from $75 to $250 per month depending on the plan's cost-sharing structure 5.

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic hypogonadism confirmed by at least two morning serum total testosterone measurements below 300 ng/dL 6. Prior authorization criteria for Jatenzo at Wyoming insurers typically mirror this guideline: documented low testosterone on two separate draws, signs and symptoms of hypogonadism, and a trial or contraindication to injectable testosterone formulations.

Blue Cross Blue Shield of Wyoming, UnitedHealthcare, and Cigna plans available through the state's ACA marketplace each maintain their own formulary decisions. Some require step therapy (failure of or intolerance to injectable testosterone cypionate or enanthate) before approving oral testosterone undecanoate 7. The American Urological Association's 2018 guideline supports multiple testosterone formulations without mandating a specific delivery route, which can be cited in appeals when step therapy denials occur 8.

If a prior authorization is denied, patients have the right to an internal appeal and, subsequently, an external review through the Wyoming Department of Insurance. Including the prescribing physician's clinical rationale, relevant lab values, and guideline references strengthens the appeal.

Wyoming Medicaid and Jatenzo

Wyoming Medicaid does not cover Jatenzo. The state's Medicaid preferred drug list excludes oral testosterone undecanoate entirely, and no exception pathway has been published for this formulation as of 2026.

Wyoming Medicaid does cover generic injectable testosterone cypionate, which remains the lowest-cost testosterone replacement option available through the program 9. For Medicaid-enrolled men who cannot tolerate injections, testosterone gel (1% or 1.62%) may be available through prior authorization, though topical formulations carry their own limitations, including transference risk to household contacts 10.

The Centers for Medicare and Medicaid Services allows states to exclude specific drugs from coverage under the Medicaid Drug Rebate Program when lower-cost therapeutic equivalents exist within the same class 11. Wyoming has exercised this option for Jatenzo. Medicare Part D plans in Wyoming may cover Jatenzo, though tier placement and out-of-pocket costs vary by plan. Men aged 65 and older should check their specific Part D formulary during open enrollment.

The Tolmar Savings Card

Tolmar Pharmaceuticals offers a manufacturer savings card for commercially insured patients that can reduce the monthly copay for Jatenzo. Eligible patients may pay as little as $75 per month, with the card covering up to a specified annual maximum 12.

Key eligibility rules apply. The card is not available to patients enrolled in any federal healthcare program, including Medicare, Medicaid, TRICARE, or the VA health system. Wyoming residents with commercial insurance who meet the eligibility criteria can activate the card through Tolmar's patient support website or through their prescribing physician's office.

One point that catches patients off guard: savings card benefits do not count toward the plan's annual deductible or out-of-pocket maximum under most accumulator adjustment programs. The Endocrine Society has noted that out-of-pocket cost is a leading driver of testosterone therapy discontinuation 13, so understanding the interaction between the savings card and your specific plan's copay accumulator policy is worth a direct call to your insurer before filling.

Compounded Oral Testosterone Undecanoate in Wyoming

Licensed 503A compounding pharmacies in Wyoming can legally prepare oral testosterone undecanoate for individual patients with a valid prescription. This is permitted under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows pharmacies to compound medications that are not commercially available in the exact prescribed form, or when a prescriber documents a clinical need 14.

The cost difference is dramatic. Compounded oral testosterone undecanoate from a Wyoming 503A pharmacy may be available at significantly reduced cost compared to brand Jatenzo. Exact pricing depends on the compounding pharmacy, dose, and capsule count.

There are tradeoffs. Compounded medications are not FDA-approved products. They do not undergo the same bioequivalence testing, manufacturing quality controls, or post-market surveillance as commercially manufactured drugs 15. The FDA has issued multiple warnings about quality variability in compounded hormone preparations. A 2020 FDA analysis found that roughly one-third of tested compounded hormone therapy products failed potency or sterility standards 16.

For men considering compounded oral testosterone undecanoate, verifying that the pharmacy holds a current Wyoming Board of Pharmacy license and carries PCAB (Pharmacy Compounding Accreditation Board) accreditation adds an additional quality checkpoint. Discussing the switch with your prescribing physician is essential, as serum testosterone monitoring should continue at the same intervals recommended for brand Jatenzo (after 1 month, then every 6 to 12 months per the Endocrine Society guideline) 17.

Telehealth Access to Jatenzo in Wyoming

Wyoming permits telehealth prescribing of testosterone replacement therapy, including Jatenzo. The state's telemedicine statutes allow licensed physicians to establish a patient-provider relationship via audiovisual communication without requiring an initial in-person visit 18.

This matters in Wyoming more than in most states. Wyoming has the lowest population density in the contiguous U.S., and many residents live hours from the nearest endocrinologist or urologist. Telehealth platforms that operate in Wyoming can prescribe Jatenzo after confirming a hypogonadism diagnosis through qualifying lab work (two morning total testosterone levels below 300 ng/dL) 19.

Once prescribed, Jatenzo can be shipped directly to a Wyoming address from a mail-order pharmacy, or the prescription can be transferred to a local retail pharmacy. Mail-order pharmacies sometimes offer modestly lower pricing or additional convenience, though savings card eligibility and insurance processing remain the same regardless of dispensing channel.

Testosterone is a Schedule III controlled substance under both federal and Wyoming state law 20. Wyoming's telehealth regulations do not prohibit the prescribing of Schedule III substances via telemedicine when the prescriber holds a valid DEA registration and Wyoming medical license. Patients should confirm that their telehealth provider meets these requirements before beginning treatment.

Clinical Considerations and Monitoring

Jatenzo's clinical profile carries specific monitoring requirements that affect the total cost of therapy beyond the drug price alone. The FDA label includes a boxed warning regarding the potential for blood pressure increases, and the prescribing information recommends monitoring blood pressure periodically during treatment 21.

In the Swerdloff et al. trial, systolic blood pressure increased by a mean of 3 to 5 mmHg in the oral testosterone undecanoate group compared to baseline 3. Hematocrit monitoring is also standard. The Endocrine Society recommends checking hematocrit at baseline, 3 to 6 months after starting therapy, and annually thereafter, given that testosterone therapy can cause polycythemia (hematocrit above 54%) 22.

A 2023 randomized controlled trial (TRAVERSE, N=5,246) provided reassurance on cardiovascular safety, finding that testosterone replacement therapy did not increase the incidence of major adverse cardiovascular events compared to placebo in men aged 45 to 80 with hypogonadism and pre-existing or high risk for cardiovascular disease 23.

Lab monitoring adds to the annual cost of testosterone therapy in Wyoming. A basic testosterone and hematocrit panel typically costs $50 to $150 per draw without insurance. Men should factor two to three lab visits per year into their total treatment budget, particularly in the first year of therapy.

Comparing Jatenzo to Other Testosterone Formulations in Wyoming

Understanding how Jatenzo stacks up against alternatives helps Wyoming patients make cost-informed decisions aligned with their clinical needs and preferences.

Injectable testosterone cypionate (generic) remains the cheapest option at $30 to $50 per month for most patients, with well-established efficacy data spanning decades 24. Injections are typically administered every 1 to 2 weeks, either at a clinic or self-administered at home.

Testosterone gel (AndroGel, Testim, or generic 1%) costs $200 to $500 per month at Wyoming retail prices without insurance. Gel formulations provide steady-state testosterone levels but carry a risk of secondary exposure to women and children through skin contact 25.

Testosterone nasal gel (Natesto) is priced at approximately $500 to $700 per month. It has the theoretical advantage of preserving spermatogenesis in some men, based on small studies, though strong long-term fertility data remain limited 26.

Jatenzo at $900 per month sits at the highest price point among commonly prescribed formulations. Its advantages are the oral route, no injection-site reactions, no transference risk, and lymphatic absorption that reduces hepatotoxicity concerns relative to older oral androgens like methyltestosterone 27.

The Endocrine Society's guideline does not recommend one testosterone formulation over another as first-line therapy, instead advising that the choice should reflect patient preference, pharmacokinetics, cost, and formulation-specific side effects 28.

Reducing Your Out-of-Pocket Cost: A Step-by-Step Approach

For Wyoming residents starting or continuing Jatenzo, the following sequence can minimize what you actually pay.

First, confirm your insurance formulary status. Call the number on the back of your insurance card and ask whether Jatenzo is covered, which tier it occupies, and whether prior authorization or step therapy applies.

Second, if covered, ask your prescriber to submit the prior authorization with two documented low testosterone values, symptom documentation, and guideline references from the Endocrine Society 29.

Third, activate the Tolmar savings card if you carry commercial insurance. Confirm with your insurer whether your plan uses a copay accumulator program, as this affects whether card benefits count toward your deductible.

Fourth, if your insurance does not cover Jatenzo or the copay remains unaffordable, discuss compounded oral testosterone undecanoate with your prescriber and identify a PCAB-accredited 503A pharmacy in Wyoming.

Fifth, if you are uninsured, compare Jatenzo cash-pay prices across Wyoming pharmacies using pricing tools, and ask your prescriber whether switching to generic injectable testosterone cypionate is clinically appropriate 30.

Patients who achieve stable eugonadal testosterone levels on Jatenzo (confirmed by a trough serum total testosterone of 300 to 1,000 ng/dL measured 4 to 6 hours post-dose) should continue monitoring per the Endocrine Society's recommended schedule: hematocrit, PSA, and testosterone levels at 3 to 6 months and then annually 31.